LEChENIE SISTEMNOY SKLERODERMII S UChETOM NATsIONAL'NYKh REKOMENDATsIY I REKOMENDATsIY EVROPEYSKOY LIGI PO BOR'BE S REVMATIZMOM (EULAR)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the current guidelines on the pharmacological treatment of systemic scleroderma according to the European League Against Rheumatism. The main groups of drugs used in various clinical manifestations of systemic scleroderma - skin lesions, sclerodermic renal crisis, pulmonary hypertension, gastro-oesophageal reflux, and arthritis - are discussed. It is emphasized that modern guidelines on the treatment of systemic scleroderma have summarized and analyzed extensive experience of foreign experts, which in combination with the experience of the national rheumatology integrated in national guidelines on rheumatology, should help the practitioner to effectively treat the patients and improve disease prognosis.

Full Text

Restricted Access

About the authors

L. P Anan'eva

Email: ananieva@irramn.ru

References

  1. Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы. М., 1993. 267 с.
  2. Ревматология: Клинические рекомендации / Под редакцией Е.Л. Насонова. М., 2010. C. 523-58.
  3. Kowal-Bielecka O., Landewe R., Avouac J., Chwiesko S., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum. Dis. 2009; 68(5): 620-28.
  4. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br. J. Rheumatol. 1996; 35(4): 364-72.
  5. Pope J.E., Bellamy N., Seibold J.R., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001; 44(6): 1351-58.
  6. Low A.H., Lee P. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis. J. Rheumatol. 2008; 35(11): 2286.
  7. Le E.N., Wigley F.M., Shah A.A., Boin F., Hummers L.K. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum. Dis. 2011; 70(6): 1104-07.
  8. Mendoza F.A., Nagle S.J., Lee J.B., Jimenez S.A. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39(6): 1241-47.
  9. Derk C.T., Huaman G., Jimenez S.A. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br. J. Dermatol. 2008; 158(5): 1063-68.
  10. Trang G., Steele R., Baron M., Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. 2012; 32(3): 645-53.
  11. Steen V.D., Medsger T.A. Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998; 41(9): 1613-19.
  12. Schiopu E., Impens A.J., Phillips K. Digital Ischemia in Scleroderma Spectrumof Diseases. Int. J. Rheumatol. 2010; pii: 923743.
  13. Bakst R., Merola J.E., Franks A.G. Jr., Sanchez M. Raynaud's phenomenon: pathogenesis and management. J. Am. Acad. Dermatol. 2008; 59: 633-53.
  14. Thompson A.E., Pope J.E. Calcium channel blockers for primary Raynaud's phenomenon: a metaanalysis. Rheumatology. 2005; 44: 145-50.
  15. Stewart M., Morling J.R. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2012; 11; 7: CD006687.
  16. Pope J., Fenlon D., Thompson A., et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 1998; issue 2: CD000953. doi: 10.1002/14651858.CD000953.
  17. Kawald A., Burmester G.R., Huscher D., Sunderkotter C., Riemerkasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J. Rheumatol. 2008; 35: 1830-37.
  18. Colaci M., Sebastiani M., Giuggioli D., Manfredi A., et al. Cardiovascular risk and prostanoids in systemic sclerosis. Clin. Exp. Rheumatol. 2008; 26(2): 333-36.
  19. Giordano N., Puccetti L., Papakostas P., DiPietra N., et al. Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. Int. J. Immunopathol. Pharmacol. 2010; 23(4): 1185-94.
  20. Matucci-Cerinic M., Denton C.P., Furst D.E., Mayes M.D., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum. Dis. 2011; 70(1): 32-8.
  21. Caglayan E., Huntgeburth M., Karasch T., et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern. Med. 2006; 166: 231-33.
  22. Herrick A.L., van den Hoogen F., Gabrielli A., Tamimi N., et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011; 63(3): 775-82.
  23. Shenoy P., Agarwal V., Kumar S., et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a doubleblind randomized cross-over trial [abstract]. Arthritis Rheum. 2008; 58(9 Suppl): S402.
  24. Hoyles R.K., Ellis R.W., Wellsbury J., et al. A Multicenter, prospective, randomized, doubleblind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthrit. Rheumatism. 2006; 12(54): 3962-70.
  25. White B., Moore W.C., Wigley F.M., et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000; 132(12): 947-54.
  26. Nannini C., West C.P., Ervin P.J., Matesson E.L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Researth & Ther 2008; 10(5).
  27. Tashkin D.P., Elashoff R., Clements P.G., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 354: 2655-66.
  28. Tzouvelekis A., Galanopoulos N., Bouros E., et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm. Med. 2012; 2012: 143637.
  29. Perez Campos D., Esteevez Del Toro M., Pena Casanovas A., et al. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Rheumatol. Clin. 2012,8(2): 58-62.
  30. Olschewski H., Simonneau G., Galie N., et.al. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 2002; 347: 322-29.
  31. Denton C.P., Pope J.E., Peter H.H., et al. L. Longterm effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis. 2008; 67: 1222-28.
  32. Badesch D.B., Hill N.S., Burgess G., et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J. Rheumatol. 2007; 34: 2417-22.
  33. Denton C.P., Lapadula G., Mouthon L., Muller-Ladner U. Renal complications and scleroderma renal crisis. Rhuuuueumatol. 2009; 48: iii32-iii35.
  34. Trang G., Steele R., Baron M., Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol. Int. 2012; 32(3): 645-53.
  35. Steen V.D., Medsger T.A. Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998; 41(9): 1613-19.
  36. Baron M., Bernier P., Cote L.F. и др. Screening and therapy for malnutrition and related gastrointestinal disorders in systemic sclerosis: recommendations of a North American expert panel. Clin. Exp. Rheumatol. 2010; 28(2 Suppl 58): S42-6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies